Last reviewed · How we verify
NCT06574698
Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma
trial testing Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy in Neuroblastoma in 64 participants. Currently enrolling.
31 December 2029
Quick facts
| Lead sponsor | Guangzhou Women and Children's Medical Center |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 64 |
| Start date | 6 May 2024 |
| Primary completion | 31 December 2029 |
| Estimated completion | 31 December 2032 |
| Sites | 1 location across China |
Drugs / interventions tested
- Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy — full drug profile →
Conditions studied
- Neuroblastoma — all drugs for Neuroblastoma →
- GD2 Antibody (Naxitamab) — all drugs for GD2 Antibody (Naxitamab) →
Sponsor
Guangzhou Women and Children's Medical Center
Who can join
Adults 1 to 21, any sex, with Neuroblastoma or GD2 Antibody (Naxitamab). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To explore the efficacy of adding anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy for newly diagnosed high risk neuroblastoma patients. To investigate wether anding Naxitamab in the induction phase will improve the response rate at the end of induction therapy and further improve the overall survival rate.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06574698
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neuroblastoma
Currently open trials in the same condition.
- NCT07399821 — An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma · Phase 1, PHASE2 · recruiting
- NCT06995872 — Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refra · Phase 1 · recruiting
- NCT06942039 — Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation · EARLY_PHASE1 · recruiting
- NCT07067346 — Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma · EARLY_PHASE1 · recruiting
- NCT07027748 — Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or R · Phase 1 · recruiting
Other Guangzhou Women and Children's Medical Center trials
Trials by the same sponsor.
- NCT07190001 — YOLT-204 in Patients With Hemoglobinopathies · EARLY_PHASE1 · not yet recruiting
- NCT06904729 — Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in Children · Phase 3 · recruiting
- NCT06948994 — A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Di · Phase 1, PHASE2 · not yet recruiting
- NCT06856759 — Single-Dose AAV-MECP2 Safety/Tolerability and Efficacy in Rett Syndrome · EARLY_PHASE1 · recruiting
- NCT06731205 — Long-term Renal Prognosis of Neonatal Acute Kidney Injury · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06574698 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangzhou Women and Children's Medical Center
- Last refreshed: 28 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06574698.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing